Search Results - "Baeuerle ∥, Patrick A."

Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? by Gires, Olivier, Pan, Min, Schinke, Henrik, Canis, Martin, Baeuerle, Patrick A.

“…EpCAM (epithelial cell adhesion molecule) was discovered four decades ago as a tumor antigen on colorectal carcinomas. Owing to its frequent and high…”
Get full text

The Emerging Role of EpCAM in Cancer and Stem Cell Signaling by MUNZ, Markus, BAEUERLE, Patrick A, GIRES, Olivier

“…Initially discovered as a dominant antigen on colon carcinomas, the epithelial cell adhesion molecule (EpCAM) was considered a mere cell adhesion molecule and…”
Get full text

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response by Baeuerle, Patrick A., Ding, Jian, Patel, Ekta, Thorausch, Niko, Horton, Holly, Gierut, Jessica, Scarfo, Irene, Choudhary, Rashmi, Kiner, Olga, Krishnamurthy, Janani, Le, Bonnie, Morath, Anna, Baldeviano, G. Christian, Quinn, Justin, Tavares, Patrick, Wei, Qi, Weiler, Solly, Maus, Marcela V., Getts, Daniel, Schamel, Wolfgang W., Hofmeister, Robert

“…T cells expressing CD19-targeting chimeric antigen receptors (CARs) reveal high efficacy in the treatment of B cell malignancies. Here, we report that T cell…”
Get full text

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing by Ross, Sandra L, Sherman, Marika, McElroy, Patricia L, Lofgren, Julie A, Moody, Gordon, Baeuerle, Patrick A, Coxon, Angela, Arvedson, Tara

“…For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with…”
Get full text

Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors by Whalen, Kerry A., Rakhra, Kavya, Mehta, Naveen K., Steinle, Alexander, Michaelson, Jennifer S., Baeuerle, Patrick A.

“…The field of immuno-oncology has revolutionized cancer patient care and improved survival and quality of life for patients. Much of the focus in the field has…”
Get full text

On the abundance of EpCAM on cancer stem cells by Gires, Olivier, Klein, Christoph A, Baeuerle, Patrick A

Get full text

Intratumoral injection and retention hold promise to improve cytokine therapies for cancer by Sauer, Karsten, Rakhra, Kavya, Wu, Kaida, Mehta, Naveen K, Michaelson, Jennifer S, Baeuerle, Patrick A

“…As powerful activators of the immune system, cytokines have been extensively explored for treating various cancers. But despite encouraging advances and some…”
Get full text

Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors by Ding, Jian, Guyette, Sarah, Schrand, Brett, Geirut, Jessica, Horton, Holly, Guo, Guangwu, Delgoffe, Greg, Menk, Ashley, Baeuerle, Patrick A., Hofmeister, Robert, Tighe, Robert

“…T cell Receptor (TCR) Fusion Construct (TRuC®) T cells harness all signaling subunits of the TCR to activate T cells and eliminate tumor cells, with minimal…”
Get full text

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells by Lutterbuese, Ralf, Raum, Tobias, Kischel, Roman, Hoffmann, Patrick, Mangold, Susanne, Rattel, Benno, Friedrich, Matthias, Thomas, Oliver, Lorenczewski, Grit, Rau, Doris, Schaller, Evelyne, Herrmann, Ines, Wolf, Andreas, Urbig, Thomas, Baeuerle, Patrick A., Kufer, Peter, Ravetch, Jeffrey V.

“…Epidermal growth factor receptor (EGFR)-specific monoclonal antibodies predominantly inhibit colorectal cancer (CRC) growth by interfering with receptor…”
Get full text

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110 by Deisting, Wibke, Raum, Tobias, Kufer, Peter, Baeuerle, Patrick A, Münz, Markus

“…Bispecific T cell engager (BiTE®) are single-chain bispecific antibody constructs with dual specificity for CD3 on T cells and a surface antigen on target…”
Get full text

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells by Herrmann, Ines, Baeuerle, Patrick A, Friedrich, Matthias, Murr, Alexander, Filusch, Susanne, Rüttinger, Dominik, Majdoub, Mariam W, Sharma, Sherven, Kufer, Peter, Raum, Tobias, Münz, Markus

“…With their resistance to genotoxic and anti-proliferative drugs and potential to grow tumors and metastases from very few cells, cancer stem or…”
Get full text

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL by Mehta, Naveen K, Pfluegler, Martin, Meetze, Kristan, Li, Bochong, Sindel, Isabelle, Vogt, Fabian, Marklin, Melanie, Heitmann, Jonas S, Kauer, Joseph, Osburg, Lukas, Zekri, Latifa, Bühring, Hans-Jörg, Mueller, Stefanie, Hörner, Sebastian, Baeuerle, Patrick A, Michaelson, Jennifer S, Jung, Gundram, Salih, Helmut R

“…BackgroundIn lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) has achieved remarkable…”
Get full text

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL by Nägele, Virginie, Kratzer, Andrea, Zugmaier, Gerhard, Holland, Chris, Hijazi, Youssef, Topp, Max S, Gökbuget, Nicola, Baeuerle, Patrick A, Kufer, Peter, Wolf, Andreas, Klinger, Matthias

“…Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory…”
Get full text

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression by Meetze, Kristan, Mehta, Naveen K, Li, Bochong, Findlay, Hannah M, London, Timothy B, Patakas, Agapitos, Michaelson, Jennifer S, Baeuerle, Patrick A

“…BackgroundDespite significant progress in the development of T cell-engaging therapies for various B-cell malignancies, a high medical need remains for the…”
Get full text

Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer by Baeuerle, Patrick A, Itin, Christian

“…Unlike any other cell type, T cells have a unique potential to eliminate cancer cells and to eventually cure cancer patients. As a result, researchers have…”
Get more information

Bispecific T-Cell Engaging Antibodies for Cancer Therapy by BAEUERLE, Patrick A, REINHARDT, Carsten

“…There is increasing evidence that T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease…”
Get full text

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies by Münz, Markus, Murr, Alexander, Kvesic, Majk, Rau, Doris, Mangold, Susanne, Pflanz, Stefan, Lumsden, John, Volkland, Jörg, Fagerberg, Jan, Riethmüller, Gert, Rüttinger, Dominik, Kufer, Peter, Baeuerle, Patrick A, Raum, Tobias

“…Epithelial cell adhesion molecule (EpCAM) is frequently and highly expressed on human carcinomas. The emerging role of EpCAM as a signalling receptor and…”
Get full text

T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities by Baeuerle, Patrick A., Wesche, Holger

“…T-cell-engaging antibodies or T-cell engagers (TCEs) can connect a patient's cytotoxic T cells with cancer cells, leading to potent redirected lysis. Until…”
Get full text

Blinatumomab: a historical perspective by Nagorsen, Dirk, Kufer, Peter, Baeuerle, Patrick A, Bargou, Ralf

“…For decades, chemotherapy has been the backbone for the treatment of patients with B cell malignancies. Depending on the individual disease, monoclonal…”
Get full text

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab by Nagorsen, Dirk, Baeuerle, Patrick A.

“…Severe side effects and few long-term remissions frequently limit the treatment of advanced malignant diseases. Bispecific antibodies are currently emerging as…”
Get full text